Sitagliptin phosphate is a Small Molecule owned by Merck & Co, and is involved in 128 clinical trials, of which 127 were completed, and 1 is ongoing.
Sitagliptin is a highly selective DPP-4 inhibitor exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones, thereby increasing the concentration and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
The revenue for Sitagliptin phosphate is expected to reach a total of $265m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sitagliptin phosphate NPV Report.
Sitagliptin phosphate Overview
Sitagliptin phosphate (Januvia / Glactiv / Istavel / Tesavel / Xelevia / Ristaben / Fazique) is an compound belongs to the beta amino acid derivative acts as anti-diabetic agent. It is formulated as film coated tablets for oral route of administration. Sitagliptin phosphate is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used in combination treatment with all oral medications for type 2 diabetes and insulin products.
Almirall is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.
The company reported revenues of (Euro) EUR827.2 million for the fiscal year ended December 2021 (FY2021), an increase of 2.4% over FY2020. In FY2021, the company’s operating margin was 0.7%, compared to an operating margin of 11.4% in FY2020. The net loss of the company was EUR40.9 million in FY2021, compared to a net profit of EUR74.3 million in FY2020. The company reported revenues of EUR197.2 million for the third quarter ended September 2022, a decrease of 54.8% over the previous quarter.
Quick View – Sitagliptin phosphate
|Highest Development Stage|